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Chemical shift imagingAbstract Intracellular fat accumulation is a common feature of liver disease. Steatosis is the his-
tological hallmark of non-alcoholic fatty liver disease (NAFLD) but also may occur with alcohol
abuse, viral hepatitis, HIV and genetic lipodystrophies, and chemotherapy. This condition is com-
mon in the Western population and is typically associated with obesity and the metabolic syndrome.
Early diagnosis and early treatment of NAFLD are important to prevent the development of end-
stage liver disease and cancer. In addition, liver fat is a risk factor for postoperative complications
after liver resection and transplantation. MRI has become a primary modality to assess hepatic ste-
atosis, both qualitatively and quantitatively. In this article we discuss various MRI methods for
evaluation of hepatic steatosis.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Radiology and Nuclear
Medicine. Open access under CC BY-NC-ND license.Contents
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Fatty liver disease refers to a spectrum of conditions character-
ized by accumulation of increasing amounts of triglycerides
within the hepatocyte. There is a wide variation in incidence
rates for NAFLD (1). An estimated prevalence of 25–35% is
seen in the general population of the United States (2).
Whereas, a study from Greece revealed evidence of steatosis
in 31% and NASH in 40% of autopsied cases of ischemic heart
disease or trafﬁc accident death after exclusion of hepatitis B
seropositivity or known liver disease (3). The prevalence of
fatty liver disease is higher among those who consume large
quantities (>60 g per day) of alcohol (45%), those with
hyperlipidemia (50%) or obesity (body mass index,
>30 kg/m2) (75%), and those with both obesity and high
alcohol consumption (95%) (4).
The exact pathogenesis of NAFLD remains poorly under-
stood. The current hypothesis by experts in the ﬁeld is that sev-
eral insults are involved in causing progressive liver injury (5).
With the initial hit, macrovesicular steatosis results. Insulin
resistance (6) most likely plays a central role in the net reten-
tion of lipids, particularly triglycerides, within the hepatocytes.
Although the mechanisms have not been completely eluci-
dated, this is thought to result from decreased disposal of fatty
acids due to impaired mitochondrial b-oxidation (7). The sec-
ond insult is generally due to oxidative stress, which causes
peroxidation of lipids in the hepatocyte membrane, cytokine
production, and Fas ligand induction (8) and is in large part
responsible for the progression from steatosis to NASH to
cirrhosis. Bacterial toxins (9), overproduction of cytokines
(especially tumor necrosis factor-a) (10), and alteration of
hepatocyte ATP stores and cytochrome P450 Cyp2E1/Cyp4A
enzyme activity (11) are also considered as potential triggers
for disease progression and ﬁbrogenesis.
Furthermore, hepatic steatosis has been reported to affect
the progression of various chronic liver diseases. For example,
hepatic steatosis has been found to adversely affect the pro-
gression of hepatic ﬁbrosis and the response to antiviral treat-
ment in patients with hepatitis C (12–14). Moreover, hepatic
steatosis has been found to be an important cofactor in liver
injury observed in patients with hemochromatosis and
alcoholic liver disease. Therefore, the assessment of hepatic
steatosis may have important clinical implications in the man-
agement of patients with chronic liver disease (15). In order to
grade steatosis, pathologists visually estimate the fraction of
hepatocytes that contain fat droplets. Typically, a ﬁve-point
ordinal scale is used (0%, 1–5%, 6–33%, 34–66%, or
>67%). The size of fat droplets is not considered (16). How-
ever, most agree that a very mild degree of steatosis involving
less than 5% of hepatocytes may not actually represent a true
pathologic abnormality (2).MRI is an attractive modality to assess hepatic steatosis. In
and out of phase MRI, calibrated with robust liver/fat stan-
dards, have been found to be superior in quantifying hepatic
steatosis, when compared with non-invasive methods (17).
Advanced MRI techniques currently under development have
demonstrated high potential for accurate detection and quan-
tiﬁcation of hepatic steatosis using proton density fat-fraction
(18). MR imaging (chemical shift imaging, multi-echo Dixon
method) and MR spectroscopy for quantifying liver fat will
be discussed in later sections.
2. Chemical shift imaging (dual echo)
On MRI, fatty liver has high signal intensity on T1-weighted
images. In addition, several MRI sequences, including fat-sup-
pression sequences and chemical shift imaging with OP gradi-
ent recalled echo sequences facilitate the detection of fat (19).
The magnitude-based approach is probably the most com-
monly used MR approach for liver fat assessment in current
practice. Typically, two gradient echoes are acquired, one
employing a TE in which the water peak (4.7 ppm) and the
dominant fat peak (1.3 ppm) are ‘‘out of phase’’ and hence
subtractive, and the other using a TE in which the two peaks
are ‘‘in phase’’ and therefore additive. Because two echoes
are acquired, this is often called ‘‘dual-phase’’ or ‘‘dual echo’’
imaging. The TE corresponding to in-phase and out-of-phase
(IOP) depend on the magnet ﬁeld strength. At 1.5 T, the chem-
ical shift between water and the dominant fat peak (3.4 ppm)
corresponds to a resonance frequency difference of 217 Hz
(i.e. the main fat peak resonates 217 Hz slower than the water
peak). Therefore, at 1.5 T, signals from water and the main fat
peak oscillate with a period of 4.6 ms (1000 ms/217 Hz). At
3 T, the chemical shift corresponds to a frequency difference
of 434 Hz (double that at 1.5 T). Therefore, the oscillation per-
iod at 3 T (2.3 ms) is half that at 1.5 T (4.6 ms) and the corre-
sponding IP and OP echo times at 3 T are halved: water and
the main fat peak are in phase every 2.3 ms (i.e., 2.3, 4.6,
and 6.9 ms) and out of phase at 1.15 ms and every subsequent
multiple of 2.3 ms (i.e., 1.15, 3.45, and 5.75 ms) (20).
To estimate the signal fat-fraction, we assume (1) the signal
intensity from fat is less than the signal intensity from water
(i.e. SFat 6 SIWater); (2) the signal intensity from OP images
represents the difference in water and fat signals (i.e., SOP =
SWater  SFat); and (3) the signal intensity from IP images
represents the sum of water and fat signals (i.e., SIP =
[SWater + SFat]) (21). Fat Signal Percentage is calculated as
[SIP  SOP]/[2 · SIP] · 100. The dynamic range of magnitude-
based chemical shift techniques has typically a 0–50% signal
fat-fraction (Figs. 1–3) (18).
The use of MR imaging with the chemical shift imaging for
the detection and quantiﬁcation of fatty liver provides the
Fig. 2 A 49 year old female with elevated LFT, biliary duct dilation, prior cholecystectomy and MR imaging done to rule out
choledocholithiasis. (a) In-phase GRE and (b) opposed-phase GRE images showing moderate hepatic steatosis with moderate signal drop
on opposed phase images. Percentage fat fraction corresponding to 30%.
Fig. 1 A 37 year old female with vague abdominal pain, evaluation of hypoechoic lesion found on recent USG. (a) In-phase GRE and
(b) opposed-phase GRE images showing mild hepatic steatosis with signal drop on opposed phase images. Percentage fat fraction
corresponding to 22%.
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entire liver, (c) minimal vulnerability to confounding factors,
and (d) absence of radiation exposure. Limitations to the
routine use of MR imaging in liver fat quantiﬁcation include
potential variability of results due to differences in MR
imaging systems, scanning parameters, and methods of
analysis (2).
3. Multi-echo Dixon sequences
This technique uses both magnitude and phase information
from three or more images acquired at echo times appropriate
for more accurate separation of water and fat signals (based on
the identiﬁcation of 3 fat peaks, rather than the commonlyused single dominant fat peak, to optimize separation of water
and fat signals) (22–26).
These methods provide estimates of fat fraction with a
dynamic range of 0–100%. While this dynamic range of
0–100% is important for imaging adipose tissue (27), it may
not be necessary for quantifying the hepatic proton density
fat fraction, which infrequently exceeds 50%. In addition to
correction for T1, T2* and the spectral complexity of fat, com-
plex-based MRI methods also require correction for noise bias
and eddy currents.
Noise bias occurs if magnitude of water and fat images are
recombined, because areas of low signal (e.g. fat signal from a
liver with no fat) have only positive noise after the magnitude
operation. Methods that create fat-fraction maps from
Fig. 3 A 46 year old female with right upper quadrant discomfort and elevated liver enzymes. (a) In-phase GRE and (b) opposed-phase GRE
images showing severe hepatic steatosis with severe signal drop on opposed phase images. Percentage fat fraction corresponding to 43%.
Fig. 4 A 33 year old male, MR imaging was done for renal cyst evaluation. PDFF map showing mild hepatic steatosis with average
PDFF value of 16 units.
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effects except near fat-fractions of 50% when the signal inten-
sity of opposed-phase images approaches zero and noise bias
impacts fat-fraction calculations. Since low fat-fractions (near
zero) are more clinically relevant, noise bias effects are moreimportant in chemical shift based water-fat separation meth-
ods (25).
Rapidly switching gradients lead to phase shifts on complex
images acquired at different echo times. These phase shifts can
corrupt estimates of fat-fraction. Eddy currents affect methods
Fig. 5 Obese female, MR imaging was done for elevated liver enzymes and recurrent abdominal pain. PDFF map showing moderate
hepatic steatosis with average PDFF value of 22 units.
Fig. 6 A 44 year old male with chronic hepatitis C for routine surveillance. PDFF map showing severe hepatic steatosis with average
PDFF value of 55 units.
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times to quantify fat such as chemical shift based water-fat
separation methods. Correction for eddy current can beperformed using a hybrid complex-magnitude approach
recently reported by Yu et al. (26). Importantly, magnitude-
based methods, including conventional IOP imaging and other
Fig. 7 A 46 year old male patient with chronic hepatitis C and elevated liver function tests, MRS with single voxel in 3 T MRI showing
moderate hepatic steatosis with increased lipid peak (marked as ‘lp’), which is nearing the level of water peak (marked as ‘H2O’).
624 K. Gangadhar et al.magnitude-based methods discard all phase information and
should be relatively immune to the effects of eddy currents
(18).
This technique utilizes a gradient echo sequence with low
ﬂip angles (FA) to minimize T1 bias, and acquires multiple
echoes at echo times at which fat and water signals are nomi-
nally in-phase or out-of-phase relative to each other. Data
obtained at each of the echo times are passed to a nonlinear
least-squares ﬁtting algorithm that estimates and corrects T2*
effects, models the fat signal as a superposition of multiple
frequency components, and estimates fat and water proton
densities from which the fat content is calculated. Using
custom analysis software, the mathematical model is applied
pixel-by-pixel on the source images to generate parametric
PDFF maps that depict the quantity and distribution of fat
throughout the entire liver. Imaging PDFF (Figs. 4–6) are
recorded in region of interest (ROI) areas placed on the PDFF
parametric maps, avoiding vessels, bile ducts, lesions and
artifacts (28).
The multi-echo method estimates FF and T2* time using
three pairs of OP and IP echoes. This method simulta-
neously estimates signal intensities of the fat and water com-
ponents and the T2* relaxation times by using least-square
ﬁtting of all six echoes as a function of the equationSI = |Sw + Sfe
2piDfTE|eTE/T2*, where Sw = SI of the water
component, Sf = SI of the fat component, Df = frequency
difference between water and methylene protons of fatty
acids, i.e. 210 Hz at 1.5 T (27). FF is calculated as
Sf/(Sw + Sf).
4. MR spectroscopy
MRI and magnetic resonance spectroscopy (MRS) provide
non-invasive means to accurately quantify intrahepatic lipid
content (29–31). In contrast to other modalities such as ultra-
sound and computed tomography (CT), MRI/MRS is capable
of detecting even small amounts of intrahepatic lipid accumu-
lation (31). Therefore, MRI/MRS is especially useful to mea-
sure changes in hepatic steatosis during various treatment
regimens. During recent years, clinical and research investiga-
tions have been performed on this subject (32).
In MRS, signals from chemicals in tissue or metabolites are
recorded. The metabolite peaks are identiﬁed primarily by
their frequencies (i.e., their position in the spectrum) and are
expressed as a shift in frequency (in parts per million [ppm])
relative to a standard of water. The most common nuclei used
for in vivo MR spectroscopy are protons (1H), sodium (23Na),
and phosphorus (31P). The advantages of 1H spectroscopy are
Fig. 8 A 43 year old female patient with right upper quadrant discomfort with elevated liver function tests, MRS with single voxel in 3 T
MRI showing severe hepatic steatosis with increased lipid peak (marked as ‘lp’) as compared to water peak (marked as ‘H2O’).
MRI evaluation of fatty liver in day to day practice 625that it is easier to perform, it is more widely available, and it
provides a much higher signal-to-noise ratio (SNR) than is
the case with 23Na and 31P. In 1H MR spectroscopy, the fre-
quency location of a metabolite or chemical compound
depends on the conﬁguration of the protons within the
chemical (33).
Two main strategies are used for single-voxel spectroscopy
(SVS) (Figs. 7 and 8) where individual voxels are analyzed:
point-resolved spectroscopy (PRESS) or stimulated-echo
acquisition mode (STEAM) (34). The PRESS acquisition
scheme (multi-echo single-shot technique) uses a 90–180–
180 pulse sequence with a long echo time (TE) and allows
for a better visualization of metabolites with long T1-relaxa-
tion times. In contrast, the STEAM sequence applies a 90–
90–90 pulse sequence and is less sensitive to J-coupling
effects, dipole–dipole coupling or spin–spin coupling. The
STEAM sequence provides shorter TE and lower signal
yield compared to PRESS, which is usually not a practical
limitation in fat quantiﬁcation in the liver. Both techniques
can be applied in intrahepatic fat quantiﬁcation in clinical
examinations (35).
5. Conclusion
MR imaging is a very sensitive and speciﬁc noninvasive modal-
ity for detection of hepatic steatosis. Chemical shift images arean efﬁcient method for screening, diagnosis and semiquantiﬁ-
cation of liver steatosis. Multi-echo Dixon MR imaging, as
proven by some recent studies, provides a technique for quan-
tifying liver fat content using proton density fat fraction that is
highly correlated with MRS, which in turn has great correla-
tion with tissue diagnosis as proven by many studies. Thus,
MR imaging is a versatile modality for hepatic quantiﬁcation
and helps in avoiding unnecessary random liver biopsies.Authors’ contributions
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